RankAlpha logo
Back to Rankings

PEPG

PepGenF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The stock is depressed versus its prior biotech valuation range, the 5 mg/kg FREEDOM2 data were clean on safety, ex-U.S. enrollment/dosing continues despite the U.S.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
10 mg/kg FREEDOM2 data may fail to show clearly improved splicing or functional benefit versus the 5 mg/kg cohort.
Momentum
33
Value
41
Sentiment
20
Setup hits (3d)
— · Net —
AI TargetsBase $1.40 · Bull $3.40 · Bear $0.60
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net —
Target $10.25
Why
Momentum33 · Δ7d -
Value41 · Δ7d -0.1
Sentiment20 · Δ7d -
So what
Weak posture. Prioritize risk control and patience.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Value · See fundamentals
Momentum
33
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
20
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 33.0 / Value 41.1 / Sentiment 20.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$155.63M
Beta
1.92
Shares Out
69.17M
P/E (TTM) · Derived
-1.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.26
Rev YoY
-
EPS YoY
-72.2%
Gross Margin
-
Op Margin
-
Net Debt
-$131.45M
Current Ratio
14.98
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology